By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...
Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on Novartis ...
April 28 (Reuters) - Swiss drugmaker Novartis reported first-quarter core operating profit and sales below market ...
The stock is down on a predictable, already-announced Entresto patent cliff (Entresto -42% YoY in Q1) and the market is ...
A U.S. federal judge rejected Novartis' efforts to block the launch of a generic version of Entresto, its blockbuster cardiovascular disease drug, per a FirstWord PHARMA report. The report noted that ...
7don MSN
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...
The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...
Novartis (NVS) stock dropped 2% as Q1 sales missed estimates at $13.11B. Entresto plunged 42% on generics while CEO warns of ...
After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.
By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results